Bristol-Myers Squibb Canada Commercializes ERBITUX(TM) for Advanced Colorectal Cancer

MONTREAL, Oct. 29 /CNW Telbec/ - In keeping with its commitment to extend and enhance the lives of Canadians through ongoing innovation, Bristol-Myers Squibb Canada (BMS) announced today the commercialization of its innovative cancer medication ERBITUX(TM) (cetuximab). This news is extremely important to Canadian physicians and their patients suffering from colorectal cancer who have exhausted other available treatments because it will give them a new option to fight this deadly disease.